GRAIL Inc.
GRAL
NASDAQ·Healthcare·Medical - Diagnostics & Research·Mkt cap $3.4B
$80.56
▲ +0.96%
P/E
-8.25
Mkt Cap
$3.4B
52-Wk Range
$31.75–$118.84
52-Week Range
$31.75 - $118.84
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Up 152.4% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
4 reasons
- Multi-cancer detection capability in single blood test
- Advanced genomic sequencing and AI-driven analysis platform
- Illumina heritage providing access to cutting-edge sequencing technology
- Large clinical validation datasets supporting test accuracy and reliability
Bear Case
1 risk
- Very high volatility (beta 3.2). Expect 3x market swings. Position size accordingly.
Growth
Stable outlook
Expanding addressable market for cancer screening in aging populations
Value
Deep value opportunity - significant discount to Life Sciences Tools peers
Momentum
Hot
+33.2% over 3m
Quality
Loss-making
Solid business
Dividend
None
No dividend
Smart-money signal
Who's buying GRAL right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Latest print - beat on both lines
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Nov 11, 2026
AUG 5, 2026
Reported EPS of -$2.56 vs -$2.66 consensus (+3.8% surprise). Revenue of $44.7M vs $42.4M expected (+5.4%). Beat on both top and bottom lines.
EPS surprise · last 4Q
1 of 1 beats
Estimate
Actual
Q3 26
+3.8%
Revenue trend · last 8Q
—
+26%
+19%
+11%
+26%
+14%
+28%
+26%
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
Q2 26
$28.7M
$38.3M
$31.8M
$35.5M
$36.2M
$43.6M
$40.8M
$44.7M
Margins · last 8Q
Gross
47.8%
Profit
-653.1%
Wall Street consensus
3 analysts · 67% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
67%
Hold
33%
Sell
0%
Median Price Target
—
Latest: TD Cowen · Jul 15, 2026
vs Industry
How GRAL stacks vs Medical - Diagnostics & Research
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.
Related